A Phase 2a Study of MRG-001 in ARDS Patients
Not Yet Recruiting Phase 2 NCT06308926
Study Description
An Early-Stage Study to Test the Safety and Effects of an Investigational Drug (MRG-001) for Patients with Acute Respiratory Distress Syndrome (ARDS)
Study Details
- Registry ID:
- NCT06308926
- Conditions:
- Acute Respiratory Distress Syndrome, Respiratory Failure, Respiratory Distress Syndrome, Respiratory Tract Diseases, Cytokine Storm
- Phase:
- Phase 2
- Target Enrollment:
- 60 participants
- Start Date:
- Age Range:
- 18–999 years
- Healthy Volunteers:
- No
Interested in Participating?
Check your eligibility and learn more about this study on TrialScreen.